Last checked at 20 Nov 2013 07:52
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Proteome Share News (PRM)
PRM Share
Price
PRM Share
News
PRM Share
Chat
PRM Share
Trades3
PRM
Live RNS
PRM Share
Charts
PRM Level 2
Console
PRM Live
Share Price
PRM Broker
Ratings
PRM Directors
Deals
PRM Financial
Diary
PRM
Fundamentals
PRM Short
Positions
PRM
Media
Proteome Information
Share Price Information for Proteome (PRM)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
4.05
Bid:
3.30
Ask:
4.80
Change:
0.19 (4.92%)
Spread:
1.50 (45.455%)
Open:
3.86
High:
0.00
Low:
0.00
Prev. Close:
3.86
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.London pre-open: Doubts about further Chinese stimulus
Mon, 20th Aug 2012 07:43
City sources predict the FTSE 100 will open up five points from Friday's close of 5,852, having gained 18 points during Friday's session following positive data from the US. Over the weekend it was reported in Europe by the Handelsblatt newspaper that the European Union could appoint the European Central Bank (ECB) as the supervisor of Europe's banking sector. Investors also took note of remarks out of Spain´s Economics Minister asking the ECB to commit to unlimited sovereign bond buying. Of interest as well, Chinese stocks fell to the lowest level since March 2009 last night after real-estate prices rose in the largest number of cities in 14 months in July, creating concerns that economic authorities may hold off on further monetary stimulus. Back in the UK, average asking prices for homes in England and Wales fell 2.4% month-on-month in August according to property website Rightmove. Values fell by 1.2% in London.In a separate report, the British Retail Consortium said visits to UK stores declined at a 2.3% year-on-year pace in the three months through July. House-builder Bovis Homes saw profits come in ahead of forecasts in the first half, helping the firm to double its interim dividend. Pre-tax profits themselves actually doubled in the six months to June 30th, up 100% from £8.1m to £16.2m. Peel Hunt was expecting a figure closer to £14.6m. Revenues gained 27% from £133.6m to £170.3m, as legal completions improved 18% from 801 homes to 944 homes with an average sales price of £164,400, up from £163,400 in the same period the year before. The dividend per share for the first half was hiked from 1.5p to 3.0p.Nanoco, the AIM-listed manufacturer of cadmium-free quantum dots and other nanomaterials, has won three grants from the UK government worth almost three-quarters of a million pounds. The grants, which total £736,000 together, were awarded by the UK's innovation agency, the Technology Strategy Board (TSB), which looks to boost the economy by stimulating and supporting business-led innovation, Nanoco said on Monday morning. Biotech group Proteome Sciences has agreed to work with CHDI Foundation Inc on a systems biology project regarding Huntington's disease. Initially, Proteome will provide its PS Biomarker Services protein profiling to CHDI's research programmes. The analyses will be performed at Proteome's facility in Frankfurt, Germany.
More News
12 Jun 2013 11:37
Proteome Sciences to develop cancer pathway profiling assays
AIM-listed biotech group Proteome Sciences has unveiled its largest contract to date comprising a technology agreement with Thermo Fisher Scientific, to develop advanced methods to profile changes in cancer pathways. Proteome Sciences said that the contract - which it valued at £2.1m - would prov
Read more18 Mar 2013 14:29
Proteome Sciences looks ahead with confidence
Drug developer Proteome Sciences has told investors that it expects strong revenue growth across the company's three main divisions in 2013 and said it is 'much encouraged by the prospects'. The announcement comes after the group received a positive response to the presentation of four posters tha
Read more31 Dec 2012 12:50
STOCKS NEWS EUROPE-UK small caps closes modestly higher
The FTSE Small Caps index closes 0.1 percent higher on Monday, New Year's Eve, tracking similar modest gains by the mid caps, also up 0.1 percent, while the blue chips shed 0.5 percent after a half-day session. The small caps index has gained 24 percent over 2012, just outperforming a 22 percent adv
Read more31 Dec 2012 10:48
Proteome delivers encouraging results from Alzheimers study
Drug maker Proteome Sciences has completed the in-vivo study of its CK1D inhibitor programme in Alzheimer's disease on time, with the results showing that both of the lead compounds for CK1D demonstrated improved cognitive function. The firm said the results provide important in-vivo proof of prin
Read more28 Sep 2012 10:46
Proteome Sciences narrows losses, bright outlook
Proteomics specialist Proteome Sciences reduced half year losses and expects second half revenues to be significantly boosted as it doubles the number of biomarker tests available from PS Biomarker Services. The group expects major licences and contracts from its proprietary biomarkers and services
Read more18 Sep 2012 10:57
Proteome stroke test could save thousands from brain damage
Medical technology group Proteome Sciences has released details of a study into a blood test which could reduce brain damage in thousands of stroke victims. The group has been collaborating with researchers at the University of Geneva to produce the test which can tell how long ago a stroke actuall
Read more20 Aug 2012 07:20
Proteome Sciences reports collaboration research agreement
Biotech group Proteome Sciences has agreed to work with CHDI Foundation Inc on a systems biology project regarding Huntington's disease. Initially, Proteome will provide its PS Biomarker Services protein profiling to CHDI's research programmes. The analyses will be performed at Proteome's facility
Read more5 Apr 2012 11:50
Proteome issues new licence for stroke product
Pharma group Proteome Sciences has granted a non-exclusive licence to UK firm Randox Laboratories for its portfolio of stroke biomarkers. Under the terms of the agreement Randox will develop products for early diagnosis of stroke and subsequent monitoring of treatment outcomes. Proteome will ear
Read more28 Mar 2012 10:46
Proteome rockets on Alzheimer's blood test
Pharma group Proteome Sciences has had a strong morning on the markets after announcing success in its project to develop better diagnostic tools for Alzheimer's disease. A study of 1,000 patients has shown three distinct "biomarkers" in people's blood which can discriminate between mild "cognitive
Read more19 Mar 2012 10:17
Stroke consortium to get €11m grant
Shares in biomarker specialist Proteome Sciences rose almost 5% on Monday morning after it announced the EU was to award €11m to a consortium of which it is a member. Euro-HYP-1, a consortium of academic, clinical and industrial European partners that includes Proteome, has been awarded the grant f
Read more27 May 2011 12:09
Proteome boosted by Sanofi settlement
Biomarker specialist Proteome Sciences is back in profit after receiving €11m from Sanofi-Aventis to settle a warranty claim. The company posted pre-tax profits of £4.59m in the year to the end of December, including the warranty claim. This compared £4.20m pre-tax loss in 2009. Revenues for 2010
Read more